OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ELUT$1.0459

Elutia Inc

PharmaceuticalsVerified

Elutia's capital structure is highly leveraged, with total liabilities of $85.66 million and total equity of -$50.30 million, indicating a negative net worth. The company's liquidity position is weak, as evidenced by a current ratio of 0.63 and a negative operating cash flow of -$2.64 million. The debt-to-equity ratio of -0.44 further highlights the company's reliance on debt financing, which is atypical for a firm with negative equity. Profitability metrics are concerning, with a net loss of $17.99 million and an operating loss of $8.48 million. The return on equity (ROE) of 0.3577 is positive but misleading due to the negative equity base. The return on assets (ROA) of -0.5089 indicates that the company is not generating returns from its asset base. Gross profit of $2.84 million is significantly lower than revenue of $6.69 million, suggesting high cost of goods sold or low pricing power. Elutia's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's financial snapshot does not provide segment-specific revenue data, but the lack of diversification increases exposure to market-specific risks. The absence of geographic breakdown suggests a potential concentration risk, particularly if the company's products are regionally dependent. The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The negative operating and free cash flows indicate a lack of internal funding for growth initiatives. The capital expenditure of -$15,000 is minimal, suggesting limited investment in long-term growth. Analysts have assigned a mean price target of $5.00, which is significantly higher than the current market price of $1.04, but the lack of strong buy recommendations (0) and the presence of only one buy recommendation suggest cautious sentiment. Risk factors include high liquidity risk due to negative net cash and a weak balance sheet. The company's dilution risk is currently low, but the negative equity position and high debt levels could necessitate future equity raises, which would dilute existing shareholders. The risk assessment flags a negative net cash position after subtracting total debt, which is a red flag for short-term solvency. Recent events include the publication of the latest financial data, which shows continued losses and a deteriorating balance sheet. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational performance. The lack of recent positive developments or guidance from management increases uncertainty for investors.

30-day price · ELUT(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyElutia Inc
TickerELUT.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Elutia Inc is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products, primarily in the areas of women's health and urology.

Classification. Elutia is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Elutia's capital structure is highly leveraged, with total liabilities of $85.66 million and total equity of -$50.30 million, indicating a negative net worth. The company's liquidity position is weak, as evidenced by a current ratio of 0.63 and a negative operating cash flow of -$2.64 million. The debt-to-equity ratio of -0.44 further highlights the company's reliance on debt financing, which is atypical for a firm with negative equity. Profitability metrics are concerning, with a net loss of $17.99 million and an operating loss of $8.48 million. The return on equity (ROE) of 0.3577 is positive but misleading due to the negative equity base. The return on assets (ROA) of -0.5089 indicates that the company is not generating returns from its asset base. Gross profit of $2.84 million is significantly lower than revenue of $6.69 million, suggesting high cost of goods sold or low pricing power. Elutia's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's financial snapshot does not provide segment-specific revenue data, but the lack of diversification increases exposure to market-specific risks. The absence of geographic breakdown suggests a potential concentration risk, particularly if the company's products are regionally dependent. The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The negative operating and free cash flows indicate a lack of internal funding for growth initiatives. The capital expenditure of -$15,000 is minimal, suggesting limited investment in long-term growth. Analysts have assigned a mean price target of $5.00, which is significantly higher than the current market price of $1.04, but the lack of strong buy recommendations (0) and the presence of only one buy recommendation suggest cautious sentiment. Risk factors include high liquidity risk due to negative net cash and a weak balance sheet. The company's dilution risk is currently low, but the negative equity position and high debt levels could necessitate future equity raises, which would dilute existing shareholders. The risk assessment flags a negative net cash position after subtracting total debt, which is a red flag for short-term solvency. Recent events include the publication of the latest financial data, which shows continued losses and a deteriorating balance sheet. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational performance. The lack of recent positive developments or guidance from management increases uncertainty for investors.
Key takeaways
  • Elutia is operating with a negative net worth and high debt levels, indicating significant financial distress.
  • The company's profitability metrics are weak, with a net loss and negative operating cash flow.
  • Revenue concentration in a single segment and lack of geographic diversification increase business risk.
  • Analysts have a cautiously optimistic view, with a mean price target of $5.00, but no strong buy recommendations.
  • The company's liquidity and solvency risks are high, with a current ratio of 0.63 and negative net cash.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$6.7M
Gross profit$2.8M
Operating income-$8.5M
Net income-$18.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$2.6M
CapEx-$15.0k
Free cash flow-$17.1M
Total assets$35.4M
Total liabilities$85.7M
Total equity-$50.3M
Cash & equivalents
Long-term debt$22.0M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$47.4M-$20.7M-$24.8M-$21.5M
FY-3$49.2M-$31.7M-$32.9M-$29.7M
FY-2$24.7M-$30.5M-$37.7M-$37.8M
FY-1$14.5M-$30.7M-$53.9M-$42.5M
FY0$12.3M-$26.9M$53.4M-$15.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$67.2M$13.5M
FY-3$68.8M-$5.0M
FY-2$43.4M-$38.6M
FY-1$36.1M-$46.3M
FY0$62.4M$27.7M
PeriodOCFCapExFCFSBC
FY-4-$15.4M-$369.0k-$21.5M
FY-3-$21.4M-$540.0k-$29.7M
FY-2-$21.8M-$346.0k-$37.8M
FY-1-$22.7M-$654.0k-$42.5M
FY0-$44.8M-$1.9M-$15.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$6.7M-$8.5M-$18.0M-$17.1M
FQ-6$6.3M-$8.5M-$28.2M-$27.5M
FQ-5$3.7M-$9.2M$1.3M$3.7M
FQ-4$2.8M-$7.5M-$9.1M-$6.4M
FQ-3$6.0M-$7.9M-$3.9M-$3.3M
FQ-2$6.3M-$9.9M-$9.6M-$8.8M
FQ-1$3.3M-$5.2M-$3.9M-$285.0k
FQ0$3.3M-$6.6M$70.8M-$7.1M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$35.4M-$50.3M
FQ-6$41.9M-$64.3M
FQ-5$48.4M-$40.2M
FQ-4$36.1M-$46.3M
FQ-3$39.3M-$36.5M
FQ-2$33.8M-$41.8M
FQ-1$29.4M-$43.9M
FQ0$62.4M$27.7M
PeriodOCFCapExFCFSBC
FQ-7-$2.6M-$15.0k-$17.1M
FQ-6-$7.0M-$13.0k-$27.5M
FQ-5-$10.4M-$560.0k$3.7M
FQ-4-$22.7M-$654.0k-$6.4M
FQ-3-$8.9M-$278.0k-$3.3M
FQ-2-$17.1M-$392.0k-$8.8M
FQ-1-$20.0M-$1.0M-$285.0k
FQ0-$44.8M-$1.9M-$7.1M
Valuation
Market price$1.04
Market cap$46.0M
Enterprise value$68.0M
P/E
Reported non-GAAP P/E
EV/Revenue10.2
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$50.3M
Net cash-$22.0M
Current ratio0.6
Debt/Equity-0.4
ROA-50.9%
ROE35.8%
Cash conversion15.0%
CapEx/Revenue-0.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricELUTActivity
Op margin-126.7%2.4% medp25 -91.8% · p75 12.5%bottom quartile
Net margin-268.8%1.2% medp25 -98.4% · p75 10.4%bottom quartile
Gross margin42.5%45.6% medp25 29.8% · p75 66.7%below median
CapEx / revenue-0.2%-5.2% medp25 -15.8% · p75 -1.7%top quartile
Debt / equity-44.0%9.3% medp25 0.1% · p75 43.8%bottom quartile
Observations
IR observations
Mean price target5.00 USD
Median price target5.00 USD
High price target5.00 USD
Low price target5.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.54 USD
Last actual EPS0.87 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 17:06 UTC#fbe9187d
Market quoteclose USD 1.00 · shares 0.04B diluted
no public URL
2026-05-16 17:06 UTC#188c5d69
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 20:43 UTCJob: 3dc6a34f